Replimune’s new melanoma data prompt a shift to NSCLC June 3, 2020 By Lee Landenberger No Comments New interim phase II data from Replimune Group Inc., of Woburn, Mass., show RP-1 and Opdivo (nivolumab, Bristol-Meyers Squibb Co.) produced multiple complete responses and a high rate of deep responses in anti-PD-1/anti-CTLA-refractory melanoma.Read More